Assessing disease-free survival intervals, which were available in no more than 40% of the patients, residual tumour burden (R1) and otherwise nuclear overexpression of survivin in central tumour areas correlated independently with limited prognosis. This evidence concerns the gene BIRC5 and neoplasm.